methyl 4-(2,2-dimethyl-4,6-dioxo-1,3-dioxan-5-ylmethyl)benzoate | 692754-49-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: methyl 4-(2,2-dimethyl-4,6-dioxo-1,3-dioxan-5-ylmethyl)benzoate
• 英文别名: 5-(4-methoxycarbonylbenzyl)-2, 2-dimethyl-1, 3-dioxane-4, 6-dione；Methyl 4-((2,2-dimethyl-4,6-dioxo-1,3-dioxan-5-yl)methyl)benzoate；methyl 4-[(2,2-dimethyl-4,6-dioxo-1,3-dioxan-5-yl)methyl]benzoate
• CAS: 692754-49-7
• 化学式: C₁₅H₁₆O₆
• 分子量: 292.288
• InChiKey: ZEPSYXGAILVZAM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  21
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  78.9
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  methyl 4-(2,2-dimethyl-4,6-dioxo-1,3-dioxan-5-ylmethyl)benzoate 在 sodium acetate 、 一水合肼 、 溶剂黄146 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 methyl 4-(3-oxo-6-phenyl-4,5-dihydro-2H-pyridazin-4-ylmethyl)benzoate
  参考文献：
  名称：

  新型 4,5-二氢-3(2H)-哒嗪酮衍生物的合成

  摘要：

  摘要 已经制备了一系列结构上与衍生自 4,5-二氢-3(2H)-哒嗪酮的非肽类血管紧张素 II (AII) 受体拮抗剂相关的新型化合物。在这些化合物中，间隔基与杂环的 C4 相连。

  DOI：

  10.1081/scc-120028351
• 作为产物：
  描述：

  对醛基苯甲酸 在 甲酸:三乙胺 1:1 、 1,8-二氮杂双环[5.4.0]十一碳-7-烯 作用下， 以 乙腈 为溶剂， 反应 73.0h， 生成 methyl 4-(2,2-dimethyl-4,6-dioxo-1,3-dioxan-5-ylmethyl)benzoate
  参考文献：
  名称：

  新型 4,5-二氢-3(2H)-哒嗪酮衍生物的合成

  摘要：

  摘要 已经制备了一系列结构上与衍生自 4,5-二氢-3(2H)-哒嗪酮的非肽类血管紧张素 II (AII) 受体拮抗剂相关的新型化合物。在这些化合物中，间隔基与杂环的 C4 相连。

  DOI：

  10.1081/scc-120028351

文献信息

• Novel Antagonists of the Glucagon Receptor
  申请人：Gomez-Galeno Jorge E.

  公开号：US20120214769A1

  公开（公告）日：2012-08-23

  The present invention provides for novel compounds of Formula (I) and pharmaceutically acceptable salts and co-crystals thereof which have glucagon receptor antagonist or inverse agonist activity. The present invention further provides for pharmaceutical compositions comprising the same as well as methods of treating, preventing, delaying the time to onset or reducing the risk for the development or progression of a disease or condition for which one or more glucagon receptor antagonist is indicated, including Type I and II diabetes, insulin resistance and hyperglycemia. The present invention also provides for processes of making the compounds of Formula I, including salts and co-crystals thereof, and pharmaceutical compositions comprising the same.

  本发明提供了式（I）的新化合物及其药学上可接受的盐和共晶体，具有胰高血糖素受体拮抗剂或反向激动剂活性。本发明还提供了包含该化合物的制药组合物，以及治疗、预防、延迟发病时间或降低一种或多种需要胰高血糖素受体拮抗剂的疾病或症状的发展或进展的方法，包括1型和2型糖尿病、胰岛素抵抗和高血糖。本发明还提供了制备式I的化合物，包括其盐和共晶体的方法，以及包含该化合物的制药组合物。
• Antagonists of the glucagon receptor
  申请人：Gomez-Galeno Jorge E.

  公开号：US08710236B2

  公开（公告）日：2014-04-29

  The present invention provides for novel compounds of Formula (I) and pharmaceutically acceptable salts and co-crystals thereof which have glucagon receptor antagonist or inverse agonist activity. The present invention further provides for pharmaceutical compositions comprising the same as well as methods of treating, preventing, delaying the time to onset or reducing the risk for the development or progression of a disease or condition for which one or more glucagon receptor antagonist is indicated, including Type I and II diabetes, insulin resistance and hyperglycemia. The present invention also provides for processes of making the compounds of Formula I, including salts and co-crystals thereof, and pharmaceutical compositions comprising the same.

  本发明提供了式(I)的新型化合物及其药学上可接受的盐和共晶体，具有胰高血糖素受体拮抗剂或逆向激动剂活性。本发明还提供了包含该化合物的制药组合物，以及治疗、预防、延缓发病时间或降低一种或多种胰高血糖素受体拮抗剂所指示的疾病或病情的风险的方法，包括I型和II型糖尿病、胰岛素抵抗和高血糖。本发明还提供了制备式(I)化合物及其盐和共晶体的方法，以及包含该化合物的制药组合物。
• NOVEL ANTAGONISTS OF THE GLUCAGON RECEPTOR
  申请人：Metabasis Therapeutics, Inc.

  公开号：US20140135400A1

  公开（公告）日：2014-05-15

  The present invention provides for novel compounds of Formula (I) and pharmaceutically acceptable salts and co-crystals thereof which have glucagon receptor antagonist or inverse agonist activity. The present invention further provides for pharmaceutical compositions comprising the same as well as methods of treating, preventing, delaying the time to onset or reducing the risk for the development or progression of a disease or condition for which one or more glucagon receptor antagonist is indicated, including Type I and II diabetes, insulin resistance and hyperglycemia. The present invention also provides for processes of making the compounds of Formula I, including salts and co-crystals thereof, and pharmaceutical compositions comprising the same.

  本发明提供了一种新型化合物Formula (I)及其药学上可接受的盐和共晶体，具有胰高血糖素受体拮抗剂或反向激动剂活性。本发明还提供了包含这些化合物的药物组合物，以及用于治疗、预防、延迟发病时间或降低一种或多种胰高血糖素受体拮抗剂适用的疾病或病症的风险，包括I型和II型糖尿病、胰岛素抵抗和高血糖的方法。本发明还提供了制备Formula (I)化合物，包括其盐和共晶体，以及包含它们的药物组合物的方法。
• Palladium-catalyzed ring-opening [5+2] annulation of vinylethylene carbonates (VECs) and C5-substituted Meldrum's acids: rapid synthesis of 7-membered lactones
  作者：Fei Li、Xin Chen、Ben-Qing Huang、Hua-Dong Xu、Chi-Fan Zhu、Mei-Hua Shen

  DOI：10.1039/d3cc05819k

  日期：——

  A novel approach for the synthesis of unsaturated 7-membered lactones by Pd-catalyzed [5+2] dipolar cycloaddition of vinylethylene carbonates (VECs) and C5-substituted Meldrum's acid derivatives has been developed. Various Meldrum's acid derivatives worked well in this reaction under mild reaction conditions. A variety of 7-membered lactones can be accessed in a facile manner in moderate to good yields

  开发了一种通过 Pd 催化乙烯基碳酸亚乙酯 (VEC) 和 C5 取代的 Meldrum 酸衍生物的 [5+2] 偶极环加成合成不饱和 7 元内酯的新方法。在温和的反应条件下，各种Meldrum酸衍生物在此反应中表现良好。通过使用容易制备的Meldrum酸衍生物，可以以中等至良好的产率以简便的方式获得各种7元内酯。
• NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF
  申请人：Mitsubishi Tanabe Pharma Corporation

  公开号：EP2172450B9

  公开（公告）日：2014-10-08